Professor Anne Hansen Ree of the CMOR Acredit team has published a paper outlining a case study on a patient with a formerly incurable metastatic colorectal cancer who was able to experience a remarkable reversal of the disease.
The patient presented to the MetAction study with extensive metastases from a resected right-sided colon cancer that were refractory to all standard therapies. The patient had the genetic profile of her metastatic disease determined in the study, which revealed a rare mutation that hinted at possible effect of cancer immune therapy. Shortly after starting such treatment the patient experienced a notable and durable response, underlining the value of applying a broad analysis of gene mutations in tumors in order to occasionally identify rare mutations that can be treated and possibly cure patients with advanced cancer using cancer immune therapy.
To read the article, please click here.